Seeing broad potential for Mitsubishi Tanabe Pharma Corp.'s oral sphingosine 1-phosphate antagonist MT-1303, Biogen Inc. agreed to pay $60 million up front and up to $484 million in additional milestones for an exclusive license to the phase II program outside Asia.